Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | IDH2 | P48735 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819357 | 0.93 | SQOR (0.48) | SQORMEN1KMT2ACA12CA1 | |
| SCHEMBL2816408 | 0.92 | SQOR (0.57) | SQORMAPTMEN1KMT2ACA2 | |
| SCHEMBL2818334 | 0.91 | MEN1 (0.47) | SQORMAPTMEN1KMT2ACA12 | |
| SCHEMBL2816422 | 0.88 | SQOR (0.48) | SQORMAPTMEN1KMT2ANPC1 | |
| SCHEMBL2817320 | 0.88 | SQOR (0.47) | SQORMEN1KMT2AIDH2ALDH1A1 | |
| SCHEMBL2820135 | 0.88 | MEN1 (0.52) | SQORMAPTMEN1KMT2ANPC1 | |
| SCHEMBL2822200 | 0.87 | SQOR (0.47) | SQORMAPTMEN1KMT2ACA12 | |
| SCHEMBL2820302 | 0.85 | KMT2A (0.46) | SQORMAPTMEN1KMT2ACA12 | |
| SCHEMBL2817281 | 0.84 | MEN1 (0.46) | SQORMAPTMEN1KMT2ACA12 | |
| SCHEMBL2818396 | 0.83 | KDR (0.46) | SQORMEN1KMT2AIDH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842809-B2 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER SCHERING PHARMA AG (DE) | 2010-11-30 | — | — | US | disclosed |
| US-7842809-B2 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER SCHERING PHARMA AG (DE) | 2010-11-30 | — | — | US | disclosed |
| US-7842809-B2 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER SCHERING PHARMA AG (DE) | 2010-11-30 | — | — | US | disclosed |
| EP-1841767-A1 | PYRAZOLOPYRIDINES, THEIR PREPARATION AND THEIR MEDICAL USE | Bayer Schering Pharma AG (DE) | 2007-10-10 | — | — | EP | disclosed |
| US-20060252754-A1 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
| WO-2006077168-A1 | PYRAZOLOPYRIDINES, THEIR PREPARATION AND THEIR MEDICAL USE | BAYER SCHERING PHARMA AG. (DE) | 2006-07-27 | — | — | WO | disclosed |
| EP-1683796-A1 | Pyrazolopyridines, their preparation and their medical use | Schering Aktiengesellschaft (DE) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252754-A1 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | TEK, TIE1, KDR | SQOR 1722/4885MAPT 1663/4885MEN1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.